|
|2 დოზა<br />4–12 კვირა<wbr /><ref>{{cite news|last1=Gallagher |first1=James |last2=Triggle |first2=Nick |date=30 December 2020 |title=Covid-19: Oxford-AstraZeneca vaccine approved for use in UK |url=https://www.bbc.com/news/health-55280671 |work=[[BBC News Online]] |access-date=5 March 2020| name-list-style = vanc}}</ref>
|2-8°C<wbr /><ref>{{cite techreport |type=Product Monograph |date=26 February 2021 |title=AstraZeneca COVID-19 Vaccine |url=https://www.azcovid-19.com/content/dam/azcovid/pdf/canada/ca-pm-azd1222-en.pdf |publisher=[[AstraZeneca]] |id=244627 |access-date=5 March 2021}}</ref>
| statusფაზა III (30,000 მონაწილე)<br>ინტერვენციული; რენდომიზებული, პლაცებოთი კონტროლირებადი კვლევა ეფეტიანობაზე, უსაფრთხოებასა და იმუნოგენურობაზე.<ref name= Overall"NCT04516746">{{#invoke:Cite efficacyweb| of|title=A 76%Phase afterIII Randomized, Double-blind, Placebo-controlled Multicenter Study in Adults to Determine the firstSafety, doseEfficacy, and 81%Immunogenicity afterof AZD1222, a secondNon-replicating doseChAdOx1 takenVector Vaccine, for the Prevention of COVID-19 |url=https://clinicaltrials.gov/ct2/show/NCT04516746 |website=[[ClinicalTrials.gov]] |id=NCT04383574 |date=12 weeksMay or2020 more|access-date=26 afterAugust the2020 |archive-date=23 August 2020 |url-status=live|archive-url=https://web.archive.org/web/20200823061231/https://clinicaltrials.gov/ct2/show/NCT04516746 }}</ref><br>მთლიანი ეფექტურობა 76% პირველი დოზის, ხოლო 81% მეორე დოზის შემდეგ (ინტერვალი 12 კვირა ან მეტი პირველი firstდოზიდან).<ref name="AZD1222-efficacy">{{cite journal | vauthors = Voysey M, Costa Clemens SA, Madhi SA, Weckx LY, Folegatti PM, Aley PK, Angus B, Baillie VL, Barnabas SL, Bhorat QE, Bibi S, Briner C, Cicconi P, Clutterbuck EA, Collins AM, Cutland CL, Darton TC, Dheda K, Dold C, Duncan CJ, Emary KR, Ewer KJ, Flaxman A, Fairlie L, Faust SN, Feng S, Ferreira DM, Finn A, Galiza E, Goodman AL, Green CM, Green CA, Greenland M, Hill C, Hill HC, Hirsch I, Izu A, Jenkin D, Joe CC, Kerridge S, Koen A, Kwatra G, Lazarus R, Libri V, Lillie PJ, Marchevsky NG, Marshall RP, Mendes AV, Milan EP, Minassian AM, McGregor A, Mujadidi YF, Nana A, Padayachee SD, Phillips DJ, Pittella A, Plested E, Pollock KM, Ramasamy MN, Ritchie AJ, Robinson H, Schwarzbold AV, Smith A, Song R, Snape MD, Sprinz E, Sutherland RK, Thomson EC, Török ME, Toshner M, Turner DP, Vekemans J, Villafana TL, White T, Williams CJ, Douglas AD, Hill AV, Lambe T, Gilbert SC, Pollard AJ | display-authors = 6 | title = Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials | journal = Lancet | volume = 397 | issue = 10277 | pages = 881–91 | date = March 2021 | pmid = 33617777 | pmc = 7894131 | doi = 10.1016/S0140-6736(21)00432-3 }}</ref> ▼|{{ClinicalStudyInfo|align=left|phase=3|participants=30000
| whenwhere=May 2020 {{snd}}Aug წლის მაისიდან 2021 წლის აგვისტომდე, Brazilბრაზილია (5,000),<ref>{{#invoke:Cite web| |title=Trial of Oxford COVID-19 vaccine starts in Brazil |url=https://covid19vaccinetrial.co.uk/brazil-trial-launch |publisher=[[Jenner Institute]] |access-date=26 August 2020 |archive-date=9 September 2020 |url-status=live|archive-url=https://web.archive.org/web/20200909025948/https://covid19vaccinetrial.co.uk/brazil-trial-launch }}</ref> Unitedგაერთიანებული Kingdomსამეფო, Indiaინდოეთი<ref>{{cite news |title=Oxford COVID-19 vaccine final trials will be held in these 17 hospitals in India |url=https://www.livemint.com/news/india/oxford-covid-19-vaccine-trials-will-be-held-in-these-17-hospitals-in-india-11597839519639.html |work=mint |date=19 August 2020 }}</ref> ▼|description=Interventional; [[randomized controlled trial|randomized, placebo-controlled study]] for efficacy, safety, and immunogenicity.<ref name="NCT04516746">{{#invoke:Cite web| |title=A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study in Adults to Determine the Safety, Efficacy, and Immunogenicity of AZD1222, a Non-replicating ChAdOx1 Vector Vaccine, for the Prevention of COVID-19 |url=https://clinicaltrials.gov/ct2/show/NCT04516746 |website=[[ClinicalTrials.gov]] |id=NCT04383574 |date=12 May 2020 |access-date=26 August 2020 |archive-date=23 August 2020 |url-status=live|archive-url=https://web.archive.org/web/20200823061231/https://clinicaltrials.gov/ct2/show/NCT04516746 }}</ref>
▲|status=Overall efficacy of 76% after the first dose and 81% after a second dose taken 12 weeks or more after the first.<ref name="AZD1222-efficacy">{{cite journal | vauthors = Voysey M, Costa Clemens SA, Madhi SA, Weckx LY, Folegatti PM, Aley PK, Angus B, Baillie VL, Barnabas SL, Bhorat QE, Bibi S, Briner C, Cicconi P, Clutterbuck EA, Collins AM, Cutland CL, Darton TC, Dheda K, Dold C, Duncan CJ, Emary KR, Ewer KJ, Flaxman A, Fairlie L, Faust SN, Feng S, Ferreira DM, Finn A, Galiza E, Goodman AL, Green CM, Green CA, Greenland M, Hill C, Hill HC, Hirsch I, Izu A, Jenkin D, Joe CC, Kerridge S, Koen A, Kwatra G, Lazarus R, Libri V, Lillie PJ, Marchevsky NG, Marshall RP, Mendes AV, Milan EP, Minassian AM, McGregor A, Mujadidi YF, Nana A, Padayachee SD, Phillips DJ, Pittella A, Plested E, Pollock KM, Ramasamy MN, Ritchie AJ, Robinson H, Schwarzbold AV, Smith A, Song R, Snape MD, Sprinz E, Sutherland RK, Thomson EC, Török ME, Toshner M, Turner DP, Vekemans J, Villafana TL, White T, Williams CJ, Douglas AD, Hill AV, Lambe T, Gilbert SC, Pollard AJ | display-authors = 6 | title = Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials | journal = Lancet | volume = 397 | issue = 10277 | pages = 881–91 | date = March 2021 | pmid = 33617777 | pmc = 7894131 | doi = 10.1016/S0140-6736(21)00432-3 }}</ref>
▲|whenwhere=May 2020{{snd}}Aug 2021, Brazil (5,000),<ref>{{#invoke:Cite web| |title=Trial of Oxford COVID-19 vaccine starts in Brazil |url=https://covid19vaccinetrial.co.uk/brazil-trial-launch |publisher=[[Jenner Institute]] |access-date=26 August 2020 |archive-date=9 September 2020 |url-status=live|archive-url=https://web.archive.org/web/20200909025948/https://covid19vaccinetrial.co.uk/brazil-trial-launch }}</ref> United Kingdom, India<ref>{{cite news |title=Oxford COVID-19 vaccine final trials will be held in these 17 hospitals in India |url=https://www.livemint.com/news/india/oxford-covid-19-vaccine-trials-will-be-held-in-these-17-hospitals-in-india-11597839519639.html |work=mint |date=19 August 2020 }}</ref>
}}
|{{ClinicalStudyInfo |phase=4 |participants=10000
|
